1. CBO (2006),Research and Development in the Pharmaceutical Industry, United States Congressional Budget Office, October, available at: www.cbo.gov/ftpdocs/76xx/doc7615/10‐02‐DrugR‐D.pdf.
2. Cohen, J., Faden, L. and Predaris, S. (2007a), “Patient access to pharmaceuticals: an international comparison”,European Journal of Health Economics, Vol. 8 No. 1, available at: http://dx.doi.org/10.1007/s10198‐006‐0028‐z.
3. Cohen, J., Paquette, C. and Cairns, C. (2007b), “Medicare formulary management: can lessons be drawn from Dutch experience with a national formulary?”,Drug Information Journal, Vol. 41 No. 2, pp. 257‐72.
4. CVZ (2004),Procedure beoordeling intramurale geneesmiddelen (“Protocol on assessment of inpatient medications”),College Voor Zorgverzekeringen (Dutch board of insurers), available at: www.cvz.nl.
5. CVZ (2006),Dutch guidelines for pharmacoeconomic research (“Dutch board of insurers”),College Voor Zorgverzekeringen, available at: www.ispor.org/PEguidelines/source/PE_guidelines_english_Netherlands.pdf.